Genentech fenebrutinib cuts relapsing MS relapses 51%-59%
04/21/2026 – 07:15 PM Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib…
Roche’s fenebrutinib cuts relapses in MS amid safety concerns
Roche is hoping to bring the the first and only high-efficacy oral for both relapsing multiple sclerosis (RMS)…
Roche fenebrutinib cuts RMS relapses 51%-59%
Roche (OTCQX: RHHBY) reported that investigational fenebrutinib met primary endpoints in Phase III…
#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring
Roche’s multiple sclerosis pill more than doubled patients’ relapse-free interval compared with Sanofi’s marketed MS pill Aubagio, according…
Genentech fenebrutinib slashes MS relapses 51%
03/02/2026 – 01:10 AM – FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by…
Roche MS drug fenebrutinib cuts relapses 51% in Phase III
Roche (OTCQX: RHHBY) reported that the pivotal Phase III study FENhance 1 met…
Roche’s OCREVUS Shows 30% Disability Reduction in Advanced PPMS Trial
Roche (OTCQX:RHHBY) presented new clinical data for OCREVUS and fenebrutinib at ECTRIMS 2025.…
Data builds on Roche’s dominance in primary progressive MS
Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in…
Roche fenebrutinib Phase III hits PPMS disability goal
Roche (OTCQX: RHHBY) reported Phase III FENtrepid results showing investigational oral BTK inhibitor…